Left Heart Disease-Related Pulmonary Hypertension

Guest editor Teresa De Marco, MD, along with Brian Shapiro, MD, Mayo Clinic, Jacksonville, FL, convened a panel of experts to discuss the challenges in diagnosis and treatment and the emerging science regarding pulmonary hypertension due to left heart disease. Contributing to the engaging discussion were James Fang, MD, University of Utah School of Medicine; Barry Borlaug, MD, Mayo Clinic, Rochester, MN; and Srinivas Murali, MD, Allegheny Health Network, Pittsburgh, PA.

Download Full-text

Pulmonary Hypertension secondary to Left Heart Disease

Current Vascular Pharmacology ◽

10.2174/1570161115666170913105424 ◽

2018 ◽

Vol 16 (6) ◽

pp. 555-560 ◽

Cited By ~ 2

Author(s):

Ghazal Kabbach ◽

Debabrata Mukherjee

Keyword(s):

Pulmonary Hypertension ◽

Heart Disease ◽

Left Heart ◽

Left Heart Disease

Download Full-text

Pulmonary Hypertension Owing to Left Heart Disease

Clinics in Chest Medicine ◽

10.1016/j.ccm.2013.09.004 ◽

2013 ◽

Vol 34 (4) ◽

pp. 683-694 ◽

Cited By ~ 1

Author(s):

Michael A. Mathier

Keyword(s):

Pulmonary Hypertension ◽

Heart Disease ◽

Left Heart ◽

Left Heart Disease

Download Full-text

Under pressure: pulmonary hypertension associated with left heart disease

European Respiratory Review ◽

10.1183/16000617.0059-2015 ◽

2015 ◽

Vol 24 (138) ◽

pp. 665-673 ◽

Cited By ~ 14

Author(s):

Harrison W. Farber ◽

Simon Gibbs

Keyword(s):

Pulmonary Hypertension ◽

Heart Disease ◽

Survival Rates ◽

Left Ventricular ◽

Left Heart ◽

Mean Pulmonary Arterial Pressure ◽

Left Heart Disease ◽

Right Heart Catheterisation ◽

Pulmonary Capillary ◽

Pulmonary Arterial

Pulmonary hypertension (PH) associated with left heart disease (PH-LHD) is the most common type of PH, but its natural history is not well understood. PH-LHD is diagnosed by right heart catheterisation with a mean pulmonary arterial pressure ≥25 mmHg and a pulmonary capillary wedge pressure >15 mmHg. The primary causes of PH-LHD are left ventricular dysfunction of systolic and diastolic origin, and valvular disease. Prognosis is poor and survival rates are low. Limited progress has been made towards specific therapies for PH-LHD, and management focuses on addressing the underlying cause of the disease with supportive therapies, surgery and pharmacological treatments. Clinical trials of therapies for pulmonary arterial hypertension in patients with PH-LHD have thus far been limited and have provided disappointing or conflicting results. Robust, long-term clinical studies in appropriate target populations have the potential to improve the outlook for patients with PH-LHD. Herein, we discuss the knowledge gaps in our understanding of PH-LHD, and describe the current unmet needs and challenges that are faced by clinicians when identifying and managing patients with this disease.

Download Full-text